

## Gambia Support for MR vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Gambia			
<b>2. Grant number:</b> 1216-GMB-09a-X			
<b>3. Date of Decision Letter:</b> 07 April 2017			
<b>4. Date of the Partnership Framework Agreement:</b> 03 February 2013			
<b>5. Programme title:</b> New vaccine support (NVS), Measles Second Dose, Measles-Rubella			
<b>6. Vaccine type:</b> Measles-Rubella			
<b>7. Requested product presentation and formulation of vaccine:</b> Measles Rubella, 10 dose(s) per vial, LYOPHILISED			
<b>8. Programme duration<sup>1</sup>:</b> 2012 -2016			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2012-2015	2016	Total <sup>2</sup>
Programme Budget (US\$)	US\$122,410 <sup>3</sup>	US\$17,500	US\$139,910
<b>10. Vaccine introduction grant (in US\$):</b> N/A			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>			
Type of supplies to be purchased with Gavi funds in each year	2012-2015	2016	
Number of vaccines doses		49,900	
Number of AD Syringes		43,000	
Number of re-constitution syringes		5,500	
Number of Safety boxes		550	
Annual Amounts (US\$)	US\$122,410 <sup>5</sup>	US\$17,500	
<b>12. Procurement agency:</b> UNICEF			
<b>13. Self-procurement:</b> N/A			
<b>14. Co-financing obligations:</b> N/A			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.


<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years.

<b>15. Operational support for campaigns:</b> N/A	
<b>16. Additional reporting requirements:</b> The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2017
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>17. Financial clarifications:</b> N/A	
<b>18. Other conditions:</b>	
Country has presented an official request to Gavi to switch from measles vaccine to measles- rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.	
	2016
Number of doses of vaccines for Measles Second Dose approved by Gavi.	49,900
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	13,383
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	21,940
Number of doses of Measles-Rubella vaccine to be funded by country.	27,960
Amount for Measles-Rubella vaccines to be funded by country in US\$ (excluding freight and insurance).	17,056
In the case of procurement through UNICEF, Gavi-funded vaccines will be purchased only after receipt of full payment of the respective amounts due from Country for the number of doses as indicated in this Decision Letter. Country is required to submit a request for a Cost Estimate to UNICEF, with a clear reference to the approval code and approval year. Country will inform Gavi Secretariat when payment of the respective amount due under this Cost Estimate has been fully made to UNICEF.	
In the event that country wishes to revert to measles vaccine, country should inform UNICEF and Gavi immediately in order to agree on an appropriate arrangement.	

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman  
Managing Director, Country Programmes  
07 April 2017